HER2 NSCLC
May 15, 2026
HER2-NSCLC Treatment Landscape: From Late-Line Breakthroughs to Frontline Transformation
Summary NSCLC accounts for nearly 80–85% of all lung cancer cases. Among these patients, HER2 mutations are identified in roughly 1–4% of cases. ENHERTU became the first FDA-approved therapy for unresectable/metastatic HER2 (ERBB2)-mutant NSCLC in 2022; however, along with recently approved HERNEXEOS and HY...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
